Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Cantor Fitzgerald
Accenture
Cipla
Mallinckrodt
Healthtrust
Novartis
Fish and Richardson
McKesson
Colorcon

Generated: October 21, 2017

DrugPatentWatch Database Preview

Ixazomib citrate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ixazomib citrate and what is the scope of ixazomib citrate freedom to operate?

Ixazomib citrate
is the generic ingredient in one branded drug marketed by Millennium Pharms and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ixazomib citrate has one hundred and eighty-nine patent family members in forty-three countries and four supplementary protection certificates in four countries.

One supplier is listed for this compound.

Summary for Generic Name: ixazomib citrate

US Patents:9
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list591
Drug Prices:see low prices
DailyMed Link:ixazomib citrate at DailyMed

Pharmacology for Ingredient: ixazomib citrate

Drug ClassProteasome Inhibitor
Mechanism of ActionProteasome Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-001Nov 20, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-001Nov 20, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-003Nov 20, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-002Nov 20, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-003Nov 20, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-001Nov 20, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-002Nov 20, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-003Nov 20, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-003Nov 20, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-003Nov 20, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: ixazomib citrate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,175,018Boronate ester compounds and pharmaceutical compositions thereof► Subscribe
8,772,536Proteasome inhibitors► Subscribe
7,576,206Proteasome inhibitors and methods of using the same► Subscribe
7,915,236Proteasome inhibitors and methods of using the same► Subscribe
2,014,018,301► Subscribe
2,015,307,523► Subscribe
8,058,262Proteasome inhibitors and methods of using the same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ixazomib citrate

Country Document Number Estimated Expiration
Japan5926319► Subscribe
Portugal1660507► Subscribe
Costa Rica11850► Subscribe
Georgia, Republic ofP20135847► Subscribe
Singapore194349► Subscribe
World Intellectual Property Organization (WIPO)2009154737► Subscribe
TaiwanI345465► Subscribe
Japan2011524903► Subscribe
Japan2007502304► Subscribe
Spain2585114► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: IXAZOMIB CITRATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017000025Germany► SubscribePRODUCT NAME: LXAZOMIB UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE UND ESTER WIE LXAZOMIBCITRAT; REGISTRATION NO/DATE: EU/1/16/1094 20161121
0871Netherlands► SubscribePRODUCT NAME: IXAZOMIB EN FARMACEUTISCH AANVAARDBARE ZOUTEN EN ESTERS DAARVAN, ZOALS IXAZOMIBCITRAAT; REGISTRATION NO/DATE: EU/1/16/1094 20161123
2017010Lithuania► SubscribePRODUCT NAME: IKSAZOMIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS IR ESTERIAI, PAVYZDZIUI KAIP IKSAZOMIBO CITRATAS; REGISTRATION NO/DATE: EU/1/16/1094 20161121
2017 00014Denmark► SubscribePRODUCT NAME: IXAZOMIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER IXAZOMIBCITRAT; REG. NO/DATE: EU/1/16/1094 20161123
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Accenture
Medtronic
McKinsey
Julphar
US Department of Justice
Cipla
AstraZeneca
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot